Rtw Investments 13F: Cuts Jade Biosciences (JBIO) Stake by $13M

RTW Investments made a big move with its stake in JBIO, slashing its holdings by 876,068 shares. This reduction, reported in its latest 13F filing with the SEC, cuts its position by about 60% as of the reporting period. RTW now holds 573,205 shares, valued at approximately $8.79 million.

What Changed in RTW Investments' JBIO Position

RTW Investments trimmed its stake in JBIO from 1,449,273 shares to 573,205 shares, a reduction of 876,068 shares. This marks a 60% decrease in their holdings. The reported value of their current position is about $8.79 million.

Other Institutional Activity in JBIO

Other funds also adjusted their positions in JBIO. FMR LLC increased its holdings by 190,935 shares, bringing its total to 7,085,423 shares, valued at roughly $99.55 million. Bellevue Group AG added 160,399 shares, ending with 3,501,502 shares worth about $49.20 million. On the other hand, Fairmount Funds Management LLC and RA Capital Management, L.P. kept their positions unchanged, holding 4,553,494 and 3,671,083 shares, respectively.

Jade Biosciences, Inc. Stock Down 9.4%

Shares of JBIO traded around $15.34 recently. The stock has been experiencing varied activity from institutional investors, as seen in recent filings. The changes in positions reflect differing views on the company's future prospects.

Insider Buying and Selling at Jade Biosciences, Inc.

Several insiders were involved in buying activities on June 9, 2026. Erin Lavelle, Lawrence Otto Klein, and Fairmount Funds Management LLC each purchased 34,843 shares. Additionally, Eric Dobmeier and Christopher Cain also bought the same number of shares. Earlier, on February 12, 2026, Bradford Dahms, the Chief Financial Officer, acquired 37,813 shares.

Analysts Set New Price Targets

Analyst firms have maintained optimistic views on JBIO. On June 2, 2026, Wedbush maintained a 'buy' rating with a $45 price target. BTIG and HC Wainwright & Co. also maintained 'buy' ratings with targets of $74 and $55 respectively on June 1, 2026. The analyst consensus suggests a positive outlook with multiple firms reiterating 'buy' ratings.

Bottom Line

RTW Investments' decision to cut its JBIO stake by 60% reflects a significant strategic shift. Investors often track these filings to gauge institutional sentiment, though it's important to remember that 13F filings are backward-looking and might not represent the current position. As JBIO's stock sees varied institutional activity, analysts remain bullish, maintaining high price targets.